EWA vs IBB
iShares MSCI Australia ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (2.86%).
Side-by-side metrics
| Metric | EWA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.86% | 0.23% |
AUM Assets under management — bigger funds are typically more liquid. | $1.35B | $7.95B |
YTD return | 15.01% | 3.10% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.02 | 0.74 |
P/E ratio | 21.07 | 23.72 |
Last price | $29.48 | $170.10 |
Inception | — | — |
Issuer | iShares | iShares |
EWA top holdings
| CBA.AX | Commonwealth Bank of Australia | 14.61% |
| BHP.AX | BHP Group Ltd | 13.71% |
| WBC.AX | Westpac Banking Corp | 6.62% |
| NAB.AX | National Australia Bank Ltd | 6.15% |
| ANZ.AX | ANZ Group Holdings Ltd | 5.55% |
| MQG.AX | Macquarie Group Ltd | 4.28% |
| WES.AX | Wesfarmers Ltd | 4.16% |
| WDS.AX | Woodside Energy Group Ltd | 3.21% |
| RIO.AX | Rio Tinto Ltd | 3.12% |
| GMG.AX | Goodman Group | 3.04% |
IBB top holdings
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.4B in assets under management, an expense ratio of 0.50%, a dividend yield of 2.86%. Its largest holding is Commonwealth Bank of Australia (CBA.AX), which represents 14.6% of the portfolio. Real Estate is the fund's largest sector exposure at 5.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.